Univariate analyses of the patients with newly detected atrial fibrillation compared with patients which remained in sinus rhythm
| . | RPM (n = 175) . | UC (n = 172) . | ||||
|---|---|---|---|---|---|---|
| . | New AF (n = 23) . | Remained SR (n = 152) . | P-value . | New AF (n = 12) . | Remained SR (n = 160) . | P-value . |
| Age (years) | 78 (68; 81) | 66 (58; 75) | <0.001 | 69 (56; 75) | 70 (62; 77) | 0.431 |
| Female sex, no. (%) | 9 (39) | 51 (34) | 0.599 | 2 (17) | 53 (33) | 0.342 |
| Laboratory measurements | ||||||
| NT-proBNP (pg/mL) | 1607 (530; 4401) | 687 (292; 1676) | 0.030 | 1553 (1243; 4099) | 627 (301; 1512) | 0.003 |
| GFR (mL/min/1.73 m2) | 40 (32; 97) | 74 (54; 99) | 0.017 | 71 (47; 90) | 63 (46; 90) | 0.520 |
| LVEF (%) | 45 (33; 60) | 40 (35; 53) | 0.187 | 40 (34; 50) | 45 (40; 55) | 0.080 |
| ȃ<40 | 6 (26) | 62 (41) | — | 6 (50) | 37 (23) | — |
| ȃ40–50 | 7 (30) | 47 (31) | — | 6 (50) | 76 (48) | — |
| ȃ>50 | 10 (44) | 43 (28) | — | 0 (0) | 47 (29) | — |
| Concomitant treatment | ||||||
| Hypertension (mmHg) | ||||||
| ȃSystolic | 125 (120;140) | 130 (119;144) | 0.442 | 145 (125;160) | 126 (110;140) | 0.045 |
| ȃDiastolic | 70 (67;80) | 79 (68;80) | 0.524 | 80 (71;90) | 74(65;80) | 0.048 |
| Diabetes | 9 (39) | 60 (40) | 0.975 | 8 (67) | 85 (53) | 0.364 |
| Hyperlipidaemia | 9 (39) | 68 (45) | 0.614 | 8 (67) | 89 (56) | 0.457 |
| Coronary artery disease | 12 (52) | 77 (51) | 0.892 | 8 (67) | 92 (58) | 0.535 |
| Myocardial infarction | 6 (26) | 33 (22) | 0.638 | 4 (33) | 36 (23) | 0.477 |
| Peripheral artery disease | 5 (22) | 18 (12) | 0.193 | 1 (8) | 25 (16) | 0.696 |
| Valvular heart disease | 12 (52) | 71 (47) | 0.625 | 4 (33) | 66 (41) | 0.764 |
| COPD | 3 (13) | 29 (19) | 0.772 | 2 (17) | 33 (21) | 1.000 |
| Stroke | 3 (13) | 9 (6) | 0.197 | 2 (17) | 15 (9) | 0.337 |
| Renal insufficiency | 15 (65) | 47 (31) | 0.001 | 6 (50) | 76 (48) | 0.867 |
| NYHA | ||||||
| ȃI | 0 (0) | 1 (1) | 0.227 | 0 (0) | 2 (1) | 0.059 |
| ȃII | 11 (48) | 99 (65) | 3 (25) | 94 (59) | ||
| ȃIII | 12 (52) | 52 (34) | 9 (75) | 64 (40) | ||
| ȃIV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Peripheral oedema | 9 (39) | 47 (31) | 0.432 | 3 (25) | 56 (35) | 0.754 |
| Dyspnoea on exertion | 21 (91) | 128 (84) | 0.535 | 12 (100) | 144 (90) | 0.606 |
| . | RPM (n = 175) . | UC (n = 172) . | ||||
|---|---|---|---|---|---|---|
| . | New AF (n = 23) . | Remained SR (n = 152) . | P-value . | New AF (n = 12) . | Remained SR (n = 160) . | P-value . |
| Age (years) | 78 (68; 81) | 66 (58; 75) | <0.001 | 69 (56; 75) | 70 (62; 77) | 0.431 |
| Female sex, no. (%) | 9 (39) | 51 (34) | 0.599 | 2 (17) | 53 (33) | 0.342 |
| Laboratory measurements | ||||||
| NT-proBNP (pg/mL) | 1607 (530; 4401) | 687 (292; 1676) | 0.030 | 1553 (1243; 4099) | 627 (301; 1512) | 0.003 |
| GFR (mL/min/1.73 m2) | 40 (32; 97) | 74 (54; 99) | 0.017 | 71 (47; 90) | 63 (46; 90) | 0.520 |
| LVEF (%) | 45 (33; 60) | 40 (35; 53) | 0.187 | 40 (34; 50) | 45 (40; 55) | 0.080 |
| ȃ<40 | 6 (26) | 62 (41) | — | 6 (50) | 37 (23) | — |
| ȃ40–50 | 7 (30) | 47 (31) | — | 6 (50) | 76 (48) | — |
| ȃ>50 | 10 (44) | 43 (28) | — | 0 (0) | 47 (29) | — |
| Concomitant treatment | ||||||
| Hypertension (mmHg) | ||||||
| ȃSystolic | 125 (120;140) | 130 (119;144) | 0.442 | 145 (125;160) | 126 (110;140) | 0.045 |
| ȃDiastolic | 70 (67;80) | 79 (68;80) | 0.524 | 80 (71;90) | 74(65;80) | 0.048 |
| Diabetes | 9 (39) | 60 (40) | 0.975 | 8 (67) | 85 (53) | 0.364 |
| Hyperlipidaemia | 9 (39) | 68 (45) | 0.614 | 8 (67) | 89 (56) | 0.457 |
| Coronary artery disease | 12 (52) | 77 (51) | 0.892 | 8 (67) | 92 (58) | 0.535 |
| Myocardial infarction | 6 (26) | 33 (22) | 0.638 | 4 (33) | 36 (23) | 0.477 |
| Peripheral artery disease | 5 (22) | 18 (12) | 0.193 | 1 (8) | 25 (16) | 0.696 |
| Valvular heart disease | 12 (52) | 71 (47) | 0.625 | 4 (33) | 66 (41) | 0.764 |
| COPD | 3 (13) | 29 (19) | 0.772 | 2 (17) | 33 (21) | 1.000 |
| Stroke | 3 (13) | 9 (6) | 0.197 | 2 (17) | 15 (9) | 0.337 |
| Renal insufficiency | 15 (65) | 47 (31) | 0.001 | 6 (50) | 76 (48) | 0.867 |
| NYHA | ||||||
| ȃI | 0 (0) | 1 (1) | 0.227 | 0 (0) | 2 (1) | 0.059 |
| ȃII | 11 (48) | 99 (65) | 3 (25) | 94 (59) | ||
| ȃIII | 12 (52) | 52 (34) | 9 (75) | 64 (40) | ||
| ȃIV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Peripheral oedema | 9 (39) | 47 (31) | 0.432 | 3 (25) | 56 (35) | 0.754 |
| Dyspnoea on exertion | 21 (91) | 128 (84) | 0.535 | 12 (100) | 144 (90) | 0.606 |
Data are presented for the RPM group and UC group, respectively. Data are presented as absolute values (per cent), mean (standard variation), or median (interquartile ranges), as appropriate. RPM, remote patient management; UC, usual care; NT-proBNP, N-terminal pro-B-type natriuretic peptide; GFR, glomerular filtration rate; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association.
Univariate analyses of the patients with newly detected atrial fibrillation compared with patients which remained in sinus rhythm
| . | RPM (n = 175) . | UC (n = 172) . | ||||
|---|---|---|---|---|---|---|
| . | New AF (n = 23) . | Remained SR (n = 152) . | P-value . | New AF (n = 12) . | Remained SR (n = 160) . | P-value . |
| Age (years) | 78 (68; 81) | 66 (58; 75) | <0.001 | 69 (56; 75) | 70 (62; 77) | 0.431 |
| Female sex, no. (%) | 9 (39) | 51 (34) | 0.599 | 2 (17) | 53 (33) | 0.342 |
| Laboratory measurements | ||||||
| NT-proBNP (pg/mL) | 1607 (530; 4401) | 687 (292; 1676) | 0.030 | 1553 (1243; 4099) | 627 (301; 1512) | 0.003 |
| GFR (mL/min/1.73 m2) | 40 (32; 97) | 74 (54; 99) | 0.017 | 71 (47; 90) | 63 (46; 90) | 0.520 |
| LVEF (%) | 45 (33; 60) | 40 (35; 53) | 0.187 | 40 (34; 50) | 45 (40; 55) | 0.080 |
| ȃ<40 | 6 (26) | 62 (41) | — | 6 (50) | 37 (23) | — |
| ȃ40–50 | 7 (30) | 47 (31) | — | 6 (50) | 76 (48) | — |
| ȃ>50 | 10 (44) | 43 (28) | — | 0 (0) | 47 (29) | — |
| Concomitant treatment | ||||||
| Hypertension (mmHg) | ||||||
| ȃSystolic | 125 (120;140) | 130 (119;144) | 0.442 | 145 (125;160) | 126 (110;140) | 0.045 |
| ȃDiastolic | 70 (67;80) | 79 (68;80) | 0.524 | 80 (71;90) | 74(65;80) | 0.048 |
| Diabetes | 9 (39) | 60 (40) | 0.975 | 8 (67) | 85 (53) | 0.364 |
| Hyperlipidaemia | 9 (39) | 68 (45) | 0.614 | 8 (67) | 89 (56) | 0.457 |
| Coronary artery disease | 12 (52) | 77 (51) | 0.892 | 8 (67) | 92 (58) | 0.535 |
| Myocardial infarction | 6 (26) | 33 (22) | 0.638 | 4 (33) | 36 (23) | 0.477 |
| Peripheral artery disease | 5 (22) | 18 (12) | 0.193 | 1 (8) | 25 (16) | 0.696 |
| Valvular heart disease | 12 (52) | 71 (47) | 0.625 | 4 (33) | 66 (41) | 0.764 |
| COPD | 3 (13) | 29 (19) | 0.772 | 2 (17) | 33 (21) | 1.000 |
| Stroke | 3 (13) | 9 (6) | 0.197 | 2 (17) | 15 (9) | 0.337 |
| Renal insufficiency | 15 (65) | 47 (31) | 0.001 | 6 (50) | 76 (48) | 0.867 |
| NYHA | ||||||
| ȃI | 0 (0) | 1 (1) | 0.227 | 0 (0) | 2 (1) | 0.059 |
| ȃII | 11 (48) | 99 (65) | 3 (25) | 94 (59) | ||
| ȃIII | 12 (52) | 52 (34) | 9 (75) | 64 (40) | ||
| ȃIV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Peripheral oedema | 9 (39) | 47 (31) | 0.432 | 3 (25) | 56 (35) | 0.754 |
| Dyspnoea on exertion | 21 (91) | 128 (84) | 0.535 | 12 (100) | 144 (90) | 0.606 |
| . | RPM (n = 175) . | UC (n = 172) . | ||||
|---|---|---|---|---|---|---|
| . | New AF (n = 23) . | Remained SR (n = 152) . | P-value . | New AF (n = 12) . | Remained SR (n = 160) . | P-value . |
| Age (years) | 78 (68; 81) | 66 (58; 75) | <0.001 | 69 (56; 75) | 70 (62; 77) | 0.431 |
| Female sex, no. (%) | 9 (39) | 51 (34) | 0.599 | 2 (17) | 53 (33) | 0.342 |
| Laboratory measurements | ||||||
| NT-proBNP (pg/mL) | 1607 (530; 4401) | 687 (292; 1676) | 0.030 | 1553 (1243; 4099) | 627 (301; 1512) | 0.003 |
| GFR (mL/min/1.73 m2) | 40 (32; 97) | 74 (54; 99) | 0.017 | 71 (47; 90) | 63 (46; 90) | 0.520 |
| LVEF (%) | 45 (33; 60) | 40 (35; 53) | 0.187 | 40 (34; 50) | 45 (40; 55) | 0.080 |
| ȃ<40 | 6 (26) | 62 (41) | — | 6 (50) | 37 (23) | — |
| ȃ40–50 | 7 (30) | 47 (31) | — | 6 (50) | 76 (48) | — |
| ȃ>50 | 10 (44) | 43 (28) | — | 0 (0) | 47 (29) | — |
| Concomitant treatment | ||||||
| Hypertension (mmHg) | ||||||
| ȃSystolic | 125 (120;140) | 130 (119;144) | 0.442 | 145 (125;160) | 126 (110;140) | 0.045 |
| ȃDiastolic | 70 (67;80) | 79 (68;80) | 0.524 | 80 (71;90) | 74(65;80) | 0.048 |
| Diabetes | 9 (39) | 60 (40) | 0.975 | 8 (67) | 85 (53) | 0.364 |
| Hyperlipidaemia | 9 (39) | 68 (45) | 0.614 | 8 (67) | 89 (56) | 0.457 |
| Coronary artery disease | 12 (52) | 77 (51) | 0.892 | 8 (67) | 92 (58) | 0.535 |
| Myocardial infarction | 6 (26) | 33 (22) | 0.638 | 4 (33) | 36 (23) | 0.477 |
| Peripheral artery disease | 5 (22) | 18 (12) | 0.193 | 1 (8) | 25 (16) | 0.696 |
| Valvular heart disease | 12 (52) | 71 (47) | 0.625 | 4 (33) | 66 (41) | 0.764 |
| COPD | 3 (13) | 29 (19) | 0.772 | 2 (17) | 33 (21) | 1.000 |
| Stroke | 3 (13) | 9 (6) | 0.197 | 2 (17) | 15 (9) | 0.337 |
| Renal insufficiency | 15 (65) | 47 (31) | 0.001 | 6 (50) | 76 (48) | 0.867 |
| NYHA | ||||||
| ȃI | 0 (0) | 1 (1) | 0.227 | 0 (0) | 2 (1) | 0.059 |
| ȃII | 11 (48) | 99 (65) | 3 (25) | 94 (59) | ||
| ȃIII | 12 (52) | 52 (34) | 9 (75) | 64 (40) | ||
| ȃIV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Peripheral oedema | 9 (39) | 47 (31) | 0.432 | 3 (25) | 56 (35) | 0.754 |
| Dyspnoea on exertion | 21 (91) | 128 (84) | 0.535 | 12 (100) | 144 (90) | 0.606 |
Data are presented for the RPM group and UC group, respectively. Data are presented as absolute values (per cent), mean (standard variation), or median (interquartile ranges), as appropriate. RPM, remote patient management; UC, usual care; NT-proBNP, N-terminal pro-B-type natriuretic peptide; GFR, glomerular filtration rate; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
